Focus on Patients

31. Call To Include More Pregnant And Breastfeeding Women In Research 11/12/2024

    In this Q&A, UCB Global Head, Women of Childbearing Age Program Marie Teil reiterates the importance of including women of childbearing age, including pregnant and breastfeding women, in clinical research and explains why it’s a priority for UCB.

32. Alexion Rethinks Diversity Metrics And Why Race Alone Isn't Enough 11/8/2024

    Clinical research does not adequately measure diversity, argues Alexion's Adrian Kielhorn. An expert in health economics and outcomes research (HEOR), Kielhorn suggests a more nuanced way of looking at diversity.

33. What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Patients? 11/4/2024

    CMO William Audeh, MD, details Agendia’s diverse, high-enrolling trial and how sponsor companies of investigational trials might benefit from its experiences. 

34. BeiGene Moves Fast, Stays In-House To Conduct Its Cancer Clinical Trials 11/1/2024

    Mark Lanasa, MD, Ph.D. explains how BeiGene gets medicines to more patients, in part by an ability to realize strategic cost and time advantages of a unique (and fast) R&D approach and by bringing clinical operations in-house. 

35. Overcoming Trial Barriers By Looking Through The Lens Of Product Adoption 10/17/2024

    In the final article of this series, Liam and Kim Eves explore how various drug candidates come inherent with barriers to adoption that directly impact how participants and providers engage with clinical research. 

36. Understanding How Strategies For Product Adoption Can Inform Clinical Trial Delivery 10/16/2024

    In part two of this series, Liam and Kim Eves discuss product archetypes and adoption drivers as they relate to commercial endeavors and looks closely at how they can be applied to clinical trial execution.

37. What Can Clinical Researchers Learn From Commercial Product Launches? 10/15/2024

    Part one of this three-part series exploring modern drug development and its impact on clinical trials and new drug launches connects product adoption concepts with much earlier clinical trial activities.

38. What's A Better Tactic For Patient Recruitment — "Unreasonable Hospitality" Or The Same Old? 10/10/2024

    When it comes to patient recruitment, which is a better strategy: sticking to the same old routine or becoming unreasonably hospitable? Consultant Ross Jackson explores both options.

39. How One Biotech Is Using FDA 505(b)(2) To Get Drugs To Patients Quicker And Cheaper 10/9/2024

    Terran Biosciences CEO Sam Clark, MD, Ph.D. explains how his team is leveraging the 505(b)(2) regulatory pathway to get its new schizophrenia drug to patients quickly and affordably. 

40. Continuing Rare Disease Treatment With A Compassionate Use Program (CUP) 10/2/2024

    Learn how Rezolute successfully led its investigational drug for treating congenital hyperinsulinism (cHI) through a compassionate use program.